New Stock Alert. It's On Fire
Read about the small cap that might make history with its nanotechnology.
Read more
Michael Castagna, insider at MannKind

Michael Castagna Insider Information

CEO of MannKind

Michael Castagna is the CEO of MannKind Corporation, a role he has held since March 2016. He also serves on the company’s board of directors.

MannKind is a biopharmaceutical company focused on discovery, development, and commercialization of therapeutics for diseases like diabetes and pulmonary arterial hypertension. In his role as CEO, Dr. Castagna is focused on strategic development of the company’s people and products.

Dr. Castagna had a 14-year career as a pharmacist with CVS before fully transitioning to the business side of the industry. Before joining MannKind, he held various executive positions at Merck Serono, Sandoz, Pharmasett, Bristol-Myers Squibb, and most recently, Amgen, where he served as vice president, global commercial lead for a portfolio of nine biosimilar drugs.

While at BMS, he helped lead the relaunch of Orencia IV and the launch of Orencia SC, both drugs targeting rheumatoid arthritis. At Sandoz, he helped relaunch its lead product, a human growth hormone called Omnitrope. 

In his free time, Castagna serves on the board of directors of Pet Partners, a nonprofit organization with a mission of improving people’s health through positive interactions with therapy animals. 

He earned his B.S. in pharmacy from the University of the Sciences in Philadelphia, his M.B.A. in entrepreneurial studies from the University of Pennsylvania’s Wharton School of Business, and his doctor of pharmacy degree from the Massachusetts College of Pharmacy and Health Sciences.

What is Michael Castagna's net worth?

The estimated net worth of Michael Castagna is at least $792,254.40 as of June 15th, 2020. Dr. Castagna owns 198,560 shares of MannKind stock worth more than $792,254 as of August 3rd. This net worth evaluation does not reflect any other investments that Dr. Castagna may own. Additionally, Dr. Castagna receives a salary of $983,000.00 as CEO at MannKind.

How old is Michael Castagna?

Dr. Castagna is currently 44 years old. There are 8 older executives and no younger executives at MannKind.

What is Michael Castagna's salary?

As the CEO of MannKind Co., Dr. Castagna earned a total compensation package of $3,563,295.00 in 2020. Dr. Castagna earned a salary of $495,192.00, stock awards of $2,580,300.00, non-equity compensation of $450,625.00, and other compensation of $37,178.00.

How do I contact Michael Castagna?

The corporate mailing address for Dr. Castagna and other MannKind executives is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. MannKind can also be reached via phone at 818-661-5000 and via email at [email protected]

Has Michael Castagna been buying or selling shares of MannKind?

Within the last three months, Michael Castagna has bought $14,950.00 of MannKind stock. Most recently, on Friday, July 30th, Michael Castagna bought 5,000 shares of MannKind stock. The stock was acquired at an average cost of $2.99 per share, with a total value of $14,950.00.

Are insiders buying or selling shares of MannKind?

In the last twelve months, MannKind insiders bought shares 7 times. They purchased a total of 54,383 shares worth mmore than $149,430.35. The most recent insider tranaction occured on July, 30th when Steven B Binder CFO bought 748 shares worth more than $2,236.52. Insiders at MannKind own 1.8 % of the company.

Information on this page was last updated on 7/30/2021.

Michael Castagna Insider Trading History at MannKind

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/30/2021Buy5,000$2.99$14,950.00View SEC Filing Icon  
3/5/2021Buy3,000$3.38$10,140.00View SEC Filing Icon  
6/15/2020Buy30,000$1.49$44,700.00198,560View SEC Filing Icon  
6/12/2020Buy68$1.41$95.88198,560View SEC Filing Icon  
1/31/2019Buy5,000$1.07$5,350.0098,157View SEC Filing Icon  
8/2/2018Buy5,000$1.31$6,550.0068,157View SEC Filing Icon  
12/20/2017Buy8,000$2.29$18,320.0035,532View SEC Filing Icon  
8/26/2016Buy17,500$0.78$13,650.00212,500View SEC Filing Icon  
8/24/2016Buy15,000$0.87$13,050.00195,000View SEC Filing Icon  
8/23/2016Buy25,000$0.94$23,500.00180,000View SEC Filing Icon  
8/12/2016Buy25,000$1.00$25,000.0075,000View SEC Filing Icon  
5/17/2016Buy50,000$0.93$46,500.0050,000View SEC Filing Icon  
See Full Table

Michael Castagna Buying and Selling Activity at MannKind

This chart shows Michael Castagna's buying and selling at MannKind by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MannKind Company Overview

MannKind logo
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Read More

Today's Range

Now: $3.99
Low: $3.94
High: $4.08

50 Day Range

MA: $4.47
Low: $3.61
High: $5.48

2 Week Range

Now: $3.99
Low: $1.52
High: $6.25

Volume

2,400,372 shs

Average Volume

4,574,713 shs

Market Capitalization

$994.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98
Read This Before You Invest In Gold
While inflation is about to hit all time highs. Many investors are thinking of putting their money into gold. But is that the best play? Maybe not, because gold prices are also at an all time high. ($2,000/oz)
Click Here To See the "Backdoor Gold Play"